Lymphoplasmacytic lymphoma history and symptoms: Difference between revisions

Jump to navigation Jump to search
Line 117: Line 117:
Less common [[symptoms]] of [[lymphoplasmacytic lymphoma]] include:<ref name="pmid11736938">{{cite journal| author=García-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A et al.| title=Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. | journal=Br J Haematol | year= 2001 | volume= 115 | issue= 3 | pages= 575-82 | pmid=11736938 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11736938  }} </ref><ref name="pmid12720138">{{cite journal| author=Merlini G, Baldini L, Broglia C, Comelli M, Goldaniga M, Palladini G et al.| title=Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. | journal=Semin Oncol | year= 2003 | volume= 30 | issue= 2 | pages= 211-5 | pmid=12720138 | doi=10.1053/sonc.2003.50064 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12720138  }} </ref>
Less common [[symptoms]] of [[lymphoplasmacytic lymphoma]] include:<ref name="pmid11736938">{{cite journal| author=García-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A et al.| title=Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. | journal=Br J Haematol | year= 2001 | volume= 115 | issue= 3 | pages= 575-82 | pmid=11736938 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11736938  }} </ref><ref name="pmid12720138">{{cite journal| author=Merlini G, Baldini L, Broglia C, Comelli M, Goldaniga M, Palladini G et al.| title=Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. | journal=Semin Oncol | year= 2003 | volume= 30 | issue= 2 | pages= 211-5 | pmid=12720138 | doi=10.1053/sonc.2003.50064 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12720138  }} </ref>
*[[Enlarged lymph nodes]] ([[Appearance|appearing]] as 1-2 inches sized [[Lump|lumps]] under the [[skin]] in [[neck]], [[groin]] or the [[armpits]]).
*[[Enlarged lymph nodes]] ([[Appearance|appearing]] as 1-2 inches sized [[Lump|lumps]] under the [[skin]] in [[neck]], [[groin]] or the [[armpits]]).
*Swollen belly/[[abdomen]] (due to [[hepatosplenomegaly]]).
*[[Swollen belly]]/[[abdomen]] (due to [[hepatosplenomegaly]]).
*[[Pain]] or a feeling of fullness below the [[ribs]] on the left side.
*[[Pain]] or a [[feeling]] of fullness below the [[ribs]] on the left side.
*Painless lumps in the [[neck]], [[underarm]], [[stomach]], or [[groin]].
*Painless [[Lump|lumps]] in the [[neck]], [[underarm]], [[stomach]], or [[groin]].
*[[Headache]].
*[[Headache]].
*Raised pink/flesh-colored [[lesions]] on [[skin]].
*Raised [[Pinks|pink]]/[[flesh]]-[[Color|colored]] [[lesions]] on [[skin]].
*[[Altered mental status]] due to decreased [[blood flow]] and [[Infiltration (medical)|infiltration]] of [[CNS]] leading to:
*[[Altered mental status]] due to decreased [[blood flow]] and [[Infiltration (medical)|infiltration]] of [[CNS]] leading to:
**[[Bing-Neel syndrome]] which includes:
**[[Bing-Neel syndrome]] which includes:
Line 128: Line 128:
***[[Memory loss]]
***[[Memory loss]]
***[[Motor disorders]]
***[[Motor disorders]]
*[[Symptoms]] resembling [[stroke]] like [[slurred speech]] or [[weakness]] on one side of [[body]] (such patients are advised to consult from their doctor right away).
*[[Symptoms]] resembling [[stroke]] like [[slurred speech]] or [[weakness]] on one side of [[body]] (such [[patients]] are advised to [[Consultation|consult]] from their [[Doctor of Medicine|doctor]] right away).
*Abnormal [[mucous membrane]] [[bleeding]] ([[epistaxis]], [[bleeding gums]]).
*[[Abnormal]] [[mucous membrane]] [[bleeding]] ([[epistaxis]], [[bleeding gums]]).
*[[Vision problems]] ([[blurred vision]], [[double vision]] or [[blind]] spots).
*[[Vision problems]] ([[blurred vision]], [[double vision]] or [[Blind spot|blind spots]]).
*[[Kidney]] problems (leading to [[weakness]], trouble [[breathing]] and [[fluid]] buildup in [[body]] [[tissues]] associated with accumulation of excess [[salt]], [[fluid]] and waste products in [[blood]] secondary to [[amyloidosis]]).
*[[Kidney]] problems (leading to [[weakness]], trouble [[breathing]] and [[fluid]] buildup in [[body]] [[tissues]] [[Association (statistics)|associated]] with accumulation of excess [[salt]], [[fluid]] and waste [[Product (chemistry)|products]] in [[blood]] [[secondary]] to [[amyloidosis]]).
*[[Heart]] problems (Secondary to [[amyloidosis]], build up of [[M protein]] in [[heart]] affects its pumping ability, and also the [[heart]] has to work harder to [[pump]] the thick [[blood]] ultimately leading to [[CHF]] with following [[symptoms]]):
*[[Heart]] problems ([[Secondary]] to [[amyloidosis]], build up of [[M protein]] in [[heart]] [[Affect|affects]] its [[Pump|pumping]] ability, and also the [[heart]] has to work harder to [[pump]] the thick [[blood]] ultimately leading to [[CHF]] with following [[symptoms]]):
**[[Palpitations]]
**[[Palpitations]]
**Feeling of [[tiredness]] and [[weakness]]
**[[Feeling]] of [[tiredness]] and [[weakness]]
**[[Cough]]
**[[Cough]]
**[[Shortness of breath]]
**[[Shortness of breath]]
**Rapid [[weight gain]]
**Rapid [[weight gain]]
**[[Swelling]] of [[feet]] and [[legs]]
**[[Swelling]] of [[feet]] and [[legs]]
*[[Infections]] (high levels of abnormal [[antibody]] in WM slows down the production of normal [[antibodies]])
*[[Infections]] (high levels of [[abnormal]] [[antibody]] in WM slows down the [[Product (biology)|production]] of [[normal]] [[antibodies]])
*[[Digestive]] problems due to deposition of [[IgM]] protein in the [[lamina propria]] of the [[intestinal wall]] include:
*[[Digestive]] problems due to [[Deposition (physics)|deposition]] of [[IgM]] [[protein]] in the [[lamina propria]] of the [[intestinal wall]] include:
**[[Diarrhea]]
**[[Diarrhea]]
**Poor absorption of [[vitamins]]
**Poor [[absorption]] of [[vitamins]]
**[[GIT]] bleeding/[[steatorrhea]] (blood in stools/dark stools)
**[[Gastrointestinal bleeding|GIT bleeding]]/[[steatorrhea]] ([[Blood in stool|blood in stools]]/[[Stools are black and tarry|dark stools]])
*Sensitivity to cold ([[Raynaud's phenomenon]] due to [[cryoglobulinemia]] in 5% WM patients), which is associated with reduced blood flow leading to [[pain]], [[itching]], [[Bluish discoloration of the skin|bluish discoloration]] or sores in following body parts:
*[[Sensitivity]] to [[cold]] ([[Raynaud's phenomenon]] due to [[cryoglobulinemia]] in 5% WM [[patients]]), which is [[Association (statistics)|associated]] with reduced [[blood flow]] leading to [[pain]], [[itching]], [[Bluish discoloration of the skin|bluish discoloration]] or [[Sore|sores]] in following [[Human body|body]] parts:
**Tip of [[nose]]
**Tip of [[nose]]
**[[Ears]]
**[[Ears]]
Line 150: Line 150:
**[[Toes]]
**[[Toes]]
*[[Clinical]] manifestations of '''[[cryoglobulinemia]]''' include:
*[[Clinical]] manifestations of '''[[cryoglobulinemia]]''' include:
**[[Numbness]] and [[tingling]] in hands and feet
**[[Numbness]] and [[tingling]] in [[hands]] and [[feet]]
**[[Joint aches]]
**[[Joint aches]]
**Small [[bruises]]
**Small [[bruises]]
Line 159: Line 159:
**[[Fever]]
**[[Fever]]
**[[Raynaud phenomenon]]
**[[Raynaud phenomenon]]
*Clinical manifestations of '''[[Cold agglutinin disease]]''' include:
*[[Clinical]] manifestations of '''[[Cold agglutinin disease]]''' include:
**[[Livedo reticularis]]
**[[Livedo reticularis]]
**[[Acrocyanosis]]
**[[Acrocyanosis]]
Line 165: Line 165:


==== Symptoms Secondary to Hyperviscosity Syndrome ====
==== Symptoms Secondary to Hyperviscosity Syndrome ====
The [[lymphoma]] cells make varying amounts of a monoclonal [[protein]] called [[immunoglobulin M]] ([[IgM]], or [[macroglobulin]]). Higher amounts of this [[protein]] than normal in [[blood]] tends to make it thick leading to [[hyperviscosity syndrome]] which occurs in approximately 15-20% patients of WM. When [[blood]] becomes thick, it is harder for [[blood]] to [[flow]] through small [[blood vessels]], and when this occurs, the condition is termed as [[Waldenström's macroglobulinemia|Waldenstrom macroglobulinemia]]. This excess amount of [[IgM]] [[antibodies]] can be ultimately associated with [[circulatory]] problems leading to less [[blood]] flow to the [[brain]], [[eyes]] or other [[organs]]. [[Clinical]] manifestations of [[hyperviscosity syndrome]] occur only if [[serum]] [[viscosity]] is >4 centipoises and include:<ref name="pmid11736938">{{cite journal| author=García-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A et al.| title=Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. | journal=Br J Haematol | year= 2001 | volume= 115 | issue= 3 | pages= 575-82 | pmid=11736938 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11736938  }} </ref>
The [[lymphoma]] [[Cells (biology)|cells]] make varying [[Amount of substance|amounts]] of a [[Monoclonal antibodies|monoclonal]] [[protein]] called [[immunoglobulin M]] ([[IgM]], or [[macroglobulin]]). Higher [[Amount of substance|amounts]] of this [[protein]] than normal in [[blood]] tends to make it thick leading to [[hyperviscosity syndrome]] which occurs in approximately 15-20% [[patients]] of WM. When [[blood]] becomes thick, it is harder for [[blood]] to [[flow]] through small [[blood vessels]], and when this occurs, the [[condition]] is termed as [[Waldenström's macroglobulinemia|Waldenstrom macroglobulinemia]]. This [[Excess risk|excess]] [[Amount of substance|amount]] of [[IgM]] [[antibodies]] can be ultimately [[Association (statistics)|associated]] with [[circulatory]] problems leading to less [[blood flow]] to the [[brain]], [[eyes]] or other [[organs]]. [[Clinical]] manifestations of [[hyperviscosity syndrome]] occur only if [[serum]] [[viscosity]] is >4 centipoises and include:<ref name="pmid11736938">{{cite journal| author=García-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A et al.| title=Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. | journal=Br J Haematol | year= 2001 | volume= 115 | issue= 3 | pages= 575-82 | pmid=11736938 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11736938  }} </ref>
*[[Symptoms]] resembling those of [[stroke]]
*[[Symptoms]] resembling those of [[stroke]]
* [[Retinal]] [[hemorrhage]] with [[Blurred vision|blurring of vision]]/[[loss of vision]]
* [[Retinal]] [[hemorrhage]] with [[Blurred vision|blurring of vision]]/[[loss of vision]]

Revision as of 21:51, 14 August 2019

Lymphoplasmacytic lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Lymphoplasmacytic Lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lymphoplasmacytic lymphoma history and symptoms On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lymphoplasmacytic lymphoma history and symptoms

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lymphoplasmacytic lymphoma history and symptoms

CDC on Lymphoplasmacytic lymphoma history and symptoms

Lymphoplasmacytic lymphoma history and symptoms in the news

Blogs on Lymphoplasmacytic lymphoma history and symptoms

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Lymphoplasmacytic lymphoma history and symptoms

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]

Overview

Many patients with lymphoplasmacytic lymphoma are asymptomatic. The disease is subtle and symptoms are nonspecific. The most common symptoms of lymphoplasmacytic lymphoma include weakness, anorexia, blurry vision, peripheral neuropathy, and weight loss. Less common symptoms of the disease include bleeding and Raynaud phenomenon.

History and Symptoms

History

Manifestations of Lymphoplasmacytic lymphoma

Following is a list of LPL manifestations with attributable causes:[3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]

Manifestations of Lymphoplasmacytic lymphoma
Cause Manifestations
Tumor infiltration
Circulating monoclonal IgM
IgM deposition into tissues
Amyloidogenic properties of IgM
Autoantibody activity of IgM

Common Symptoms

Common symptoms of lymphoplasmacytic lymphoma include:[1][25]

Less Common Symptoms

Less common symptoms of lymphoplasmacytic lymphoma include:[1][25]

Symptoms Secondary to Hyperviscosity Syndrome

The lymphoma cells make varying amounts of a monoclonal protein called immunoglobulin M (IgM, or macroglobulin). Higher amounts of this protein than normal in blood tends to make it thick leading to hyperviscosity syndrome which occurs in approximately 15-20% patients of WM. When blood becomes thick, it is harder for blood to flow through small blood vessels, and when this occurs, the condition is termed as Waldenstrom macroglobulinemia. This excess amount of IgM antibodies can be ultimately associated with circulatory problems leading to less blood flow to the brain, eyes or other organs. Clinical manifestations of hyperviscosity syndrome occur only if serum viscosity is >4 centipoises and include:[1]

References

  1. 1.0 1.1 1.2 1.3 García-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A; et al. (2001). "Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases". Br J Haematol. 115 (3): 575–82. PMID 11736938.
  2. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M (2000). "Waldenström's macroglobulinemia: clinical features, complications, and management". J Clin Oncol. 18 (1): 214–26. doi:10.1200/JCO.2000.18.1.214. PMID 10623712.
  3. Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP (2005). "Diagnosis and management of Waldenstrom's macroglobulinemia". J Clin Oncol. 23 (7): 1564–77. doi:10.1200/JCO.2005.03.144. PMID 15735132.
  4. Dimopoulos, Meletios A.; Panayiotidis, Panayiotis; Moulopoulos, Lia A.; Sfikakis, Petros; Dalakas, Marinos (2000). "Waldenström's Macroglobulinemia: Clinical Features, Complications, and Management". Journal of Clinical Oncology. 18 (1): 214–214. doi:10.1200/JCO.2000.18.1.214. ISSN 0732-183X.
  5. Kyle RA, Garton JP (1987). "The spectrum of IgM monoclonal gammopathy in 430 cases". Mayo Clin Proc. 62 (8): 719–31. PMID 3110508.
  6. Lin P, Bueso-Ramos C, Wilson CS, Mansoor A, Medeiros LJ (2003). "Waldenstrom macroglobulinemia involving extramedullary sites: morphologic and immunophenotypic findings in 44 patients". Am J Surg Pathol. 27 (8): 1104–13. PMID 12883242.
  7. Dimopoulos MA, Alexanian R (1994). "Waldenstrom's macroglobulinemia". Blood. 83 (6): 1452–9. PMID 8123836.
  8. Fudenberg HH, Virella G (1980). "Multiple myeloma and Waldenström macroglobulinemia: unusual presentations". Semin Hematol. 17 (1): 63–79. PMID 6767276.
  9. Fadil A, Taylor DE (1998). "The lung and Waldenström's macroglobulinemia". South Med J. 91 (7): 681–5. PMID 9671845.
  10. Veltman GA, van Veen S, Kluin-Nelemans JC, Bruijn JA, van Es LA (1997). "Renal disease in Waldenström's macroglobulinaemia". Nephrol Dial Transplant. 12 (6): 1256–9. PMID 9198063.
  11. Daoud MS, Lust JA, Kyle RA, Pittelkow MR (1999). "Monoclonal gammopathies and associated skin disorders". J Am Acad Dermatol. 40 (4): 507–35, quiz 536-8. PMID 10188670.
  12. Orellana J, Friedman AH (1981). "Ocular manifestations of multiple myeloma, Waldenström's macroglobulinemia and benign monoclonal gammopathy". Surv Ophthalmol. 26 (3): 157–69. PMID 6801795.
  13. Civit T, Coulbois S, Baylac F, Taillandier L, Auque J (1997). "[Waldenström's macroglobulinemia and cerebral lymphoplasmocytic proliferation: Bing and Neel syndrome. Apropos of a new case]". Neurochirurgie. 43 (4): 245–9. PMID 9686227.
  14. Kwaan HC, Bongu A (1999). "The hyperviscosity syndromes". Semin Thromb Hemost. 25 (2): 199–208. doi:10.1055/s-2007-994921. PMID 10357087.
  15. Farhangi M, Merlini G (1986). "The clinical implications of monoclonal immunoglobulins". Semin Oncol. 13 (3): 366–79. PMID 3094151.
  16. "Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 3-1990. A 66-year-old woman with Waldenström's macroglobulinemia, diarrhea, anemia, and persistent gastrointestinal bleeding". N Engl J Med. 322 (3): 183–92. 1990. doi:10.1056/NEJM199001183220308. PMID 2104668.
  17. Gertz, M A; Kyle, R A; Noel, P (1993). "Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia". Journal of Clinical Oncology. 11 (5): 914–920. doi:10.1200/JCO.1993.11.5.914. ISSN 0732-183X.
  18. Gertz MA, Kyle RA (2003). "Amyloidosis with IgM monoclonal gammopathies". Semin Oncol. 30 (2): 325–8. doi:10.1053/sonc.2003.50060. PMID 12720162.
  19. Gardyn J, Schwartz A, Gal R, Lewinski U, Kristt D, Cohen AM (2001). "Waldenström's macroglobulinemia associated with AA amyloidosis". Int J Hematol. 74 (1): 76–8. PMID 11530809.
  20. Ropper AH, Gorson KC (1998). "Neuropathies associated with paraproteinemia". N Engl J Med. 338 (22): 1601–7. doi:10.1056/NEJM199805283382207. PMID 9603799.
  21. Vital A (2001). "Paraproteinemic neuropathies". Brain Pathol. 11 (4): 399–407. PMID 11556684.
  22. Crisp D, Pruzanski W (1982). "B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins)". Am J Med. 72 (6): 915–22. PMID 6807086.
  23. Lindström FD, Hed J, Eneström S (1980). "Renal pathology of Waldenström's macroglobulinaemia with monoclonal antiglomerular antibodies and nephrotic syndrome". Clin Exp Immunol. 41 (2): 196–204. PMC 1537007. PMID 6777101.
  24. Sen HN, Chan CC, Caruso RC, Fariss RN, Nussenblatt RB, Buggage RR (2004). "Waldenström's macroglobulinemia-associated retinopathy". Ophthalmology. 111 (3): 535–9. doi:10.1016/j.ophtha.2003.05.036. PMID 15019332.
  25. 25.0 25.1 Merlini G, Baldini L, Broglia C, Comelli M, Goldaniga M, Palladini G; et al. (2003). "Prognostic factors in symptomatic Waldenstrom's macroglobulinemia". Semin Oncol. 30 (2): 211–5. doi:10.1053/sonc.2003.50064. PMID 12720138.

Template:WH Template:WS